USE OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-N-4-METHYL-3-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL¨-BENZAMIDE TO INHIBIT THE TYROSINE KINASE RECEPTOR C-FMS

This invention relates to the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide (also known as imatinib, gleevec, glivec, cgp57148b or STI571), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatm...

Full description

Saved in:
Bibliographic Details
Main Authors LYONS, ALAN, BRUCE, DEWAR, ANDREA, LOUIS, HUGHES, TIMOTHY, PETER
Format Patent
LanguageEnglish
French
German
Published 22.12.2010
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:This invention relates to the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide (also known as imatinib, gleevec, glivec, cgp57148b or STI571), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of c-fms-associated diseases including; choriocarcinoma, malignant histiocytosis, embryonal carcinoma, endometrial carcinoma, brain microglial tumours, sarcoidosis, microglial cell involvement in normal and variant Creutzfeld-Jacob disease, and amyotrophic lateral sclerosis.
Bibliography:Application Number: EP20050793868